Cargando…

Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy

BACKGROUND: While novel drugs have been developed, docetaxel remains one of the standard initial systemic therapies for castration-resistant prostate cancer (CRPC) patients. Despite the excellent anti-tumor effect of docetaxel, its severe adverse effects sometimes distress patients. Therefore, it wo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yamashita, Shimpei, Kohjimoto, Yasuo, Iguchi, Takashi, Koike, Hiroyuki, Kusumoto, Hiroki, Iba, Akinori, Kikkawa, Kazuro, Kodama, Yoshiki, Matsumura, Nagahide, Hara, Isao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4802623/ https://www.ncbi.nlm.nih.gov/pubmed/27001073 http://dx.doi.org/10.1186/s12894-016-0133-y

Ejemplares similares

Zoledronic acid prevents decreases in bone mineral density in patients with prostate cancer undergoing combined androgen blockade
por: Nishizawa, Satoshi, et al.
Publicado: (2014)

Transplantation of Horseshoe Kidney from Living, Genetically Unrelated Donor
por: Kikkawa, Kazuro, et al.
Publicado: (2015)

Necrotizing fasciitis after high-dose rate brachytherapy and external beam radiation for prostate cancer: a case report
por: Yamashita, Shimpei, et al.
Publicado: (2017)

Myosteatosis as a novel prognostic biomarker after radical cystectomy for bladder cancer
por: Yamashita, Shimpei, et al.
Publicado: (2020)

Usefulness of Preoperative High Systemic Immune-Inflammation Index as a Prognostic Biomarker in Patients Who Undergo Radical Cystectomy for Bladder Cancer: Multicenter Analysis
por: Yamashita, Shimpei, et al.
Publicado: (2021)

Enzalutamide Versus Abiraterone as a First-Line Endocrine Therapy for Castration-Resistant Prostate Cancer: Protocol for a Multicenter Randomized Phase 3 Trial
por: Hara, Isao, et al.
Publicado: (2018)

Bladder neck size and its association with urinary continence after robot‐assisted radical prostatectomy
por: Kohjimoto, Yasuo, et al.
Publicado: (2022)

The Importance of Follow-Up and Evaluation of Intraoperative Findings to Determine Surgical Indications for Retractile Testis
por: Kikkawa, Kazuro, et al.
Publicado: (2023)

Noncontrast Computed Tomography Parameters for Predicting Shock Wave Lithotripsy Outcome in Upper Urinary Tract Stone Cases
por: Yamashita, Shimpei, et al.
Publicado: (2018)

Prognostic Impact of Lymphatic Invasion in Patients with High-Risk Prostate Cancer after Robot-Assisted Radical Prostatectomy and Extended Lymph Node Dissection: A Single-Institution Prospective Cohort Study
por: Yamashita, Shimpei, et al.
Publicado: (2022)

Upper urinary tract stone disease in patients with poor performance status: active stone removal or conservative management?
por: Yamashita, Shimpei, et al.
Publicado: (2017)

Undifferentiated pleomorphic sarcoma of the prostate in a young man
por: Iwahashi, Yuya, et al.
Publicado: (2020)

Adrenocortical carcinoma with inferior vena cava tumor thrombus found during surgery
por: Nabeshima, Yuta, et al.
Publicado: (2022)

Essential roles of oncostatin M receptor β signaling in renal crystal formation in mice
por: Yamashita, Shimpei, et al.
Publicado: (2020)

Dynamic Changes in Fluid Temperatures during Laser Irradiation Using Various Laser Modes: A Thermography-Based In Vitro Phantom Study
por: Yamashita, Shimpei, et al.
Publicado: (2023)

A randomized phase III trial of personalized peptide vaccination for castration-resistant prostate cancer progressing after docetaxel
por: Noguchi, Masanori, et al.
Publicado: (2021)

Disseminated carcinomatosis of the bone marrow caused by prostate cancer diagnosed with only bone marrow biopsy
por: Wakamiya, Takahito, et al.
Publicado: (2021)

External validation of risk classification in patients with docetaxel-treated castration-resistant prostate cancer
por: Nakano, Kazuhiko, et al.
Publicado: (2014)

Real-World Treatment Patterns in Men with Castration- Resistant Prostate Cancer Receiving Docetaxel
por: Davis, Keith L., et al.
Publicado: (2015)

Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
por: Francini, Filippo, et al.
Publicado: (2011)

Docetaxel with or without estramustine for estramustine refractory castration-resistant prostate cancer: a single institution experience
por: Nakano, Kazuhiko, et al.
Publicado: (2012)

Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer
por: Mahon, K L, et al.
Publicado: (2015)

Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancer
por: Wilson, C, et al.
Publicado: (2008)

Docetaxel in very elderly men with metastatic castration-resistant prostate cancer
por: Wong, Hui-Li, et al.
Publicado: (2015)

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2019)

γ-Klotho is correlated with resistance to docetaxel in castration-resistant prostate cancer
por: Onishi, Kenta, et al.
Publicado: (2020)

Cabazitaxel versus docetaxel for treatment of metastatic castrate refractory prostate cancer
por: James, Nicholas D., et al.
Publicado: (2022)

Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study
por: Petrioli, R, et al.
Publicado: (2011)

Efficacy of Androgen Deprivation Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Docetaxel-Based Chemotherapy
por: Min, Kyungchan, et al.
Publicado: (2020)

Relationships of body composition and adipocytokines with outcomes in metastatic castration-resistant prostate cancer patients receiving docetaxel chemotherapy
por: Li, Jun-Hong, et al.
Publicado: (2023)

Clinical activity of abiraterone plus prednisone in docetaxel-naïve and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer
por: Lin, Guo-Wen, et al.
Publicado: (2019)

Inhibition of Hsp90 Augments Docetaxel Therapy in Castrate Resistant Prostate Cancer
por: Ku, ShengYu, et al.
Publicado: (2014)

The Influence of Prednisone on the Efficacy of Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer
por: Teply, Benjamin A., et al.
Publicado: (2015)

Inhibiting autophagy overcomes docetaxel resistance in castration-resistant prostate cancer cells
por: Wang, Quan, et al.
Publicado: (2018)

Efficacy and Safety of Docetaxel in Elderly Patients With Metastatic Castration-Resistant Prostate Cancer
por: Maia, Manuel Caitano, et al.
Publicado: (2017)

Curcumin Nanoparticles and Their Cytotoxicity in Docetaxel-Resistant Castration-Resistant Prostate Cancer Cells
por: Tanaudommongkon, Irin, et al.
Publicado: (2020)

The Effects of Matrine in Combination with Docetaxel on Castration-Resistant (Androgen-Independent) Prostate Cancer
por: Li, Qi, et al.
Publicado: (2019)

Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer
por: Mout, Lisanne, et al.
Publicado: (2020)

Real-world evaluation of upfront docetaxel in metastatic castration-sensitive prostate cancer
por: Isaksson, Jenny, et al.
Publicado: (2021)

Dnajb8, a Member of the Heat Shock Protein 40 Family Has a Role in the Tumor Initiation and Resistance to Docetaxel but Is Dispensable for Stress Response
por: Yamashita, Masamichi, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_s6vlfrms548sa82gt1nclk13ql